Farge D, Julien J
Hôpital Saint-Louis, service de médecine interne du Pr Rouffy, Paris.
Rev Prat. 1994 Feb 15;44(4):454-8.
Following organ transplantation, repeated measurements of blood pressure are an essential part of monitoring as they enable arterial hypertension, the most frequent complication in these patients, to be detected and treated at an early stage. De novo occurrence of arterial hypertension, directly due to the use of cyclosporin, is observed in more than two-thirds of these patients during the first post-transplantation year. This predominantly diastolic arterial hypertension is usually mild to moderate, but it has repercussions on graft function and requires a specific treatment appropriate to the severity of arterial hypertension and to its physiological mechanism depending on the organ transplanted. Arterial hypertension is caused by the nephrotoxicity of cyclosporin and by its intrarenal and peripheral vasoconstrictive activity. Stimulation of the renin-angiotensin system associated with stimulation of the sympathetic system and blood volume expansion play a major role in the genesis and maintenance of de novo arterial hypertension which constitutes a new model of drug-induced hypertension. Treatment of de novo arterial hypertension rests on arteriole-dilating antihypertensive drugs such as calcium channel blockers or angiotensin-converting enzyme inhibitors used as first-line therapy and sometimes combined with another drug. In case of severe and uncontrolled arterial hypertension, the other classes of antihypertensive drugs can be used as second treatment.
器官移植后,反复测量血压是监测的重要组成部分,因为这能早期发现并治疗这些患者最常见的并发症——动脉高血压。超过三分之二的患者在移植后的第一年出现直接由使用环孢素引起的新发动脉高血压。这种以舒张期为主的动脉高血压通常为轻至中度,但会对移植物功能产生影响,需要根据动脉高血压的严重程度及其生理机制(取决于移植的器官)进行特定治疗。动脉高血压是由环孢素的肾毒性及其肾内和外周血管收缩活性引起的。肾素 - 血管紧张素系统的激活,以及交感神经系统的刺激和血容量扩张,在新发动脉高血压的发生和维持中起主要作用,这构成了药物性高血压的一种新模式。新发动脉高血压的治疗依赖于扩张小动脉的降压药物,如钙通道阻滞剂或血管紧张素转换酶抑制剂作为一线治疗药物,有时会与另一种药物联合使用。对于严重且难以控制的动脉高血压,可使用其他类别的降压药物作为二线治疗。